Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404247 | 1.00 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL20240364 | 1.00 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL680614 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3825519 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL2099474 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL11287494 | 0.96 | GSR (0.57) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL11287492 | 0.96 | GSR (0.57) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL16194521 | 0.93 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL997560 | 0.93 | GSR (0.52) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL29075853 | 0.93 | GSR (0.52) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118974058-A | Preparation method and crystalline form of (6A, 12A) -17-amino-12-methyl-6, 15-bis (trifluoromethyl) -13, 19-dioxa-3,4,18-triazatricyclo [12.3.1.12,5] nonadeca-1 (18), 2,4,14,16-pentaen-6-ol | 弗特克斯药品有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118695873-A | Pharmaceutical composition comprising human hyaluronidase PH20 and a drug | 阿特根公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2024113429-A1 | TARGETED BIONIC POLYPEPTIDE NANO DELIVERY CARRIER, NANO NUCLEIC ACID DELIVERY SYSTEM, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳先进技术研究院 | 2024-06-06 | — | — | WO | claimed |
| CN-117534581-A | Process for preparing L-lysine monohydrate | 湖北葛店人福药用辅料有限责任公司 | 2024-02-09 | — | — | CN | claimed |
| CN-116603072-A | Method for preparing functionalized nano material by ring-opening polymerization induction of phenylalanine anhydride initiated by water-soluble photosensitizer | 大连工业大学 | 2023-08-18 | — | — | CN | claimed |
| CN-116196294-A | Amphiphilic polyamino acid drug-loaded nano-particle with stimulus responsiveness and preparation method thereof | 宁德师范学院 | 2023-06-02 | — | — | CN | claimed |
| CN-116139104-A | Targeting bionic polypeptide nano delivery carrier, nano nucleic acid delivery system, preparation method and application thereof | 深圳先进技术研究院 | 2023-05-23 | — | — | CN | claimed |
| CN-114524932-A | Amphiphilic triblock polyamino acid copolymer, intermediate, preparation and application | 宁德师范学院 | 2022-05-24 | — | — | CN | claimed |
| CN-105797140-B | Stable formulations of hyaluronan degrading enzymes | 哈洛齐梅公司 | 2020-08-11 | — | — | CN | claimed |
| US-9993529-B2 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME, INC. (US) | 2018-06-12 | — | — | US | claimed |
| CN-103100093-A | Load small interfering RNA nanoscale lipid microbubble ultrasonic contrast agent and preparation method | THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY | 2013-05-15 | — | — | CN | claimed |
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | claimed |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-10 | — | — | US | claimed |
| WO-2012174478-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | claimed |
| CN-101044188-A | Process for preparing glatiramer | SANDOZ AG (CH) | 2007-09-26 | — | — | CN | claimed |
| CN-1308690-C | Novel method and kit for sequencing polypeptides | PROCTER & GAMBLE (US) | 2007-04-04 | — | — | CN | claimed |
| CN-1551984-A | Novel method and kit for sequencing polypeptides | — | 2004-12-01 | — | — | CN | claimed |
| EP-0182356-B2 | Nutrient compositions | MONTEFIORE HOSPITAL ASS OF WES (US) | 1998-08-05 | — | — | EP | claimed |
| US-5034377-A | Dipeptides and tripeptides for use as nutrients in diets | MONTEFIORE HOSPITAL ASSOCIATION OF WESTERN PENNSYLVANIA (US) | 1991-07-23 | — | — | US | claimed |
| EP-0182356-A2 | Nutrient compositions | The Montefiore Hospital Association of Western Pennsylvania (US) | 1986-05-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | IDE, MMP20, IDUA | GSR 4631/4885RNPEP 36/4885GNAI3 4512/4885 |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | IDE, IDUA, MMP20 | GSR 4741/4885RNPEP 39/4885GNAI3 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.